Ask AI
ProCE Banner Activity

Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

PDF

Questa risorsa adatta ai pazienti riassume i risultati chiave e i punti principali di ogni studio sulla leucemia linfatica cronica o sul linfoma linfocitario piccolo. Queste risorse distillano ogni studio in un documento scaricabile per la comunicazione con il paziente, per preparare i pazienti e i loro operatori sanitari a importanti conversazioni per decisioni condivise.

Released: April 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL

Disclosure

Primary Author

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.